DLBCL
Showing 1 - 25 of 915
Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With
Completed
- DLBCL
- Old Age; Debility
-
Homburg, Saarland, GermanySaarland University Medical Center
Nov 20, 2023
DLBCL - Diffuse Large B Cell Lymphoma, Lymphoma Trial in Shanghai (Other)
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Lymphoma
- Other
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Sep 6, 2023
Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)
Not yet recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Sep 18, 2023
DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Chidamide
- +3 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Apr 10, 2023
Diffuse Large B-cell Lymphoma (DLBCL) Trial in Lanzhou (Zanubrutinib)
Not yet recruiting
- Diffuse Large B-cell Lymphoma (DLBCL)
-
Lanzhou, Gansu, ChinaThe First Hospital of Lanzhou University
Oct 23, 2022
Orelabrutinib in Combination With Standard Treatment Regimen for
Not yet recruiting
- Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Aug 23, 2023
Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:
Completed
- Diffuse Large B-cell Lymphoma
-
East Hanover, New JerseyNovartis
Jun 16, 2023
DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)
Not yet recruiting
- Diffuse Large B-Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
-
Jinan, Shandong, ChinaAffiliated Cancer Hospital of Shandong First Medical University
May 16, 2023
Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)
Recruiting
- Diffuse Large B Cell Lymphoma,DLBCL
- PM 8.4 mg/m2
- PM 11.2 mg/m2
-
Chengdu, Sichuan, ChinaWest China Hospital Sichuan University
Jan 15, 2023
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)
Recruiting
- DLBCL
- +3 more
-
Minneapolis, MinnesotaUniversity of Minnesota, Masonic Cancer Center
Jul 1, 2022
Large B-cell Lymphoma, DLBCL Trial in New York (89Zr-DFO-REGN3767, PET/CT)
Recruiting
- Large B-cell Lymphoma
- DLBCL
- 89Zr-DFO-REGN3767
- PET/CT
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 3, 2022
Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Zanubrutinib
- +5 more
-
Shenyang, Liaoning, ChinaXing Xiaojing
Jun 1, 2023
Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)
Recruiting
- Diffuse Large B Cell Lymphoma
- Itacitinib
- Chimeric antigen receptor (CAR) T-cell therapy
-
Tampa, FloridaMoffitt Cancer Center
Mar 6, 2023
Lymphomas Non-Hodgkin's B-Cell Trial in Ballarat, Box Hill, Heidelberg (Avelumab)
Active, not recruiting
- Lymphomas Non-Hodgkin's B-Cell
-
Ballarat, Victoria, Australia
- +2 more
Jan 30, 2023
Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023
Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma
Completed
- Diffuse Large B-cell Lymphoma (DLBCL)
- CAR-T
- Allo-HSCT cohort
-
East Hanover, New JerseyNovartis Investigative Site
Jun 29, 2022
DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))
Recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- Follicular Lymphoma
- Lenalidomide combined with G-CHOP (LO CHOP)
-
Xiamen, Fujian, ChinaBing Xu
Nov 28, 2023
Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)
Recruiting
- Diffuse Large B Cell Lymphoma
- +2 more
- Rituximab
- +5 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Dec 12, 2022
Including miRNA-based Tumor Signatures in Diffuse Large B Cell
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- no intervention (observational study)
-
Napoli, Italy
- +2 more
Feb 17, 2023
Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 9, 2023
DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Orelabrutinib
- +2 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Aug 10, 2022
Diffuse Large B Cell Lymphoma (DLBCL) Trial in Shanghai (Orelabrutinib + R-CHOP, Placebo + R-CHOP)
Recruiting
- Diffuse Large B Cell Lymphoma (DLBCL)
- Orelabrutinib + R-CHOP
- Placebo + R-CHOP
-
Shanghai, Shanghai, ChinaShanghai Ruijing Hospital
Nov 28, 2022
DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)
Recruiting
- DLBCL
- Tafasitamab and Lenalidomide
-
Hangzhou, Zhejiang, ChinaThe First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022
DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)
Not yet recruiting
- DLBCL
- Selinexor combined with Prednisone, Etoposide, and Lenalidomide
-
Qingdao, Shandong, Chinathe affiliated hospital of Qingdao University
Aug 18, 2022